Leflunomide for kids with stubborn Henoch-Schonlein purpura rash
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial looks at whether leflunomide can calm Henoch-Schonlein purpura (a childhood rash condition) when the rash is hard to control. If standard treatments don’t stop new or worsening rash, this study may offer another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 1 and 18 years old.
- Doctors have diagnosed Henoch-Schonlein purpura (HSP).
- The rash is “refractory,” meaning it stays bad or keeps coming back despite treatment with steroids and other usual care.
- A parent or guardian agrees to treatment and signs the consent form.
- Your child is not allergic to leflunomide.
- Your child has no serious major illnesses like severe heart, liver, kidney, immune problems, serious infections, or a recent organ transplant, and the team feels it is safe to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether leflunomide can safely help children with idiopathic pulmonary hemosiderosis (a condition where the lungs bleed, and iron builds up). The study is mainly about safety and early signs of benefit in young patients.
This trial looks at whether mycophenolate mofetil can help children ages 3–18 who have Henoch-Schönlein purpura affecting the gut that does not improve with steroid treatment. It may help reduce serious stomach symptoms like severe belly pain, bleeding, or bowel problems.
This study tests a combination of two medicines, rituximab and low-dose mycophenolate, to treat a type of kidney inflammation called proliferative lupus nephritis in children. It aims to see if the combination works well and is safe for kids with active lupus affecting the kidneys.
This study tests anifrolumab, a new injection medicine that may help control systemic lupus erythematosus (SLE) in children and teens. Researchers will measure how the body processes the medicine and whether it helps reduce lupus activity while monitoring for side effects.
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
This study looks at how your genes might affect how well leflunomide works for rheumatoid arthritis. It is for Pakistani adults who are starting or recently started leflunomide, and will help doctors understand who might respond best.
Hear when a new Henoch-Schonlein Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.